Bayer AG (BAYN.XE) Thursday said it is seeking European marketing authorization for its anti-clotting pill Xarelto to treat pulmonary embolism which, if approved, would boost the potential blockbuster drug's use in the E.U. to four indications from just three at present. The filing "has the potential to further extend the benefits of rivaroxaban [marketed as Xarelto] to an even wider patient population," Bayer said in a statement. The filing is supported by a study that was presented in March involving some 4,800 patients with pulmonary embolism, a blood clot on the lung.